Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $282.02 USD
Change Today -13.89 / -4.69%
Volume 1.4M
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

intercept pharmaceuticals in (ICPT) Snapshot

Open
$283.03
Previous Close
$295.91
Day High
$289.00
Day Low
$278.02
52 Week High
08/12/14 - $349.08
52 Week Low
12/3/14 - $128.50
Market Cap
6.7B
Average Volume 10 Days
917.0K
EPS TTM
$-15.02
Shares Outstanding
23.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERCEPT PHARMACEUTICALS IN (ICPT)

intercept pharmaceuticals in (ICPT) Related Businessweek News

No Related Businessweek News Found

intercept pharmaceuticals in (ICPT) Details

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. It primarily develops obeticholic acid (OCA), a bile acid analog that completed Phase III clinical trial for the treatment of primary biliary cirrhosis; is in Phase III clinical trial for the treatment of nonalcoholic steatohepatitis; is in Phase 2 clinical trial for primary sclerosing cholangitis; and is in Phase I clinical trial for the treatment of biliary atresia. The company’s product candidates in preclinical stage include INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of fibrosis; and INT-777, an orally administered TGR5 agonist used in treating type 2 diabetes. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

136 Employees
Last Reported Date: 03/2/15
Founded in 2002

intercept pharmaceuticals in (ICPT) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $934.0K
Chief Financial Officer, Treasurer and Secret...
Total Annual Compensation: $556.9K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $626.5K
Compensation as of Fiscal Year 2013.

intercept pharmaceuticals in (ICPT) Key Developments

Intercept Announces New Data Analyses from FLINT Trial of Obeticholic Acid in NASH

Intercept Pharmaceuticals, Inc. announced new subgroup analyses from the Phase 2b FLINT trial of obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis (NASH). Intercept is presenting the data in two posters during this poster session at the American Association for the Study of Liver Disease (AASLD) and Industry Colloquium: Novel Targets and Therapies in Liver Disease. Obeticholic acid (OCA) is a first-in-class farnesoid X receptor (FXR) agonist being developed for primary biliary cirrhosis (PBC), NASH and other chronic liver indications. Intercept has initiated a rolling New Drug Application with the FDA for PBC, and expects to complete the NDA and MAA submission in Second Quarter 2015. The commercial launch of OCA in the U.S. and Europe is planned in 2016.

Intercept Pharmaceuticals, Inc. - Special Call

To discuss new subgroup analyses from the Phase 2b FLINT trial of obeticholic acid in patients with nonalcoholic steatohepatitis

Intercept Pharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Intercept Pharmaceuticals, Inc. announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported licensing revenue of $445,000 against $405,000 a year ago. Net loss attributable to common stockholders was $34,824,000 or $1.63 per basic and diluted share against $12,369,000 or $0.64 per basic and diluted share a year ago. For the year, the company reported licensing revenue of $1,742,000 against $1,622,000 a year ago. Net loss attributable to common stockholders was $283,226,000 or $13.63 per basic and diluted share against $67,792,000 or $3.76 per basic and diluted share a year ago. The 2014 net loss includes $170.8 million of non-cash warrant revaluation expense, an increase of $142.4 million from 2013, and $20.1 million in non-cash stock-based compensation expense, an increase of $10.7 million from 2013. During 2014, expenditures in the OCA development program increased by $34.8 million as Intercept focused its resources on completing the work and studies necessary for its planned New Drug Application and Marketing Authorization Application filings for OCA for the treatment of PBC, which are currently planned to be completed during the first half of 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICPT:US $282.02 USD -13.89

ICPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICPT.
View Industry Companies
 

Industry Analysis

ICPT

Industry Average

Valuation ICPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3,632.9x
Price/Book 27.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3,708.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERCEPT PHARMACEUTICALS IN, please visit www.interceptpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.